Get instant notifications when there’s news about your stocks. Claim your 1 week free trial StreetInsider Premium here.
AUSTIN, TX Oct. 05, 2022 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat treatments for cancer, announced today that dr. Andrew Brenner, MD, Ph.D., Professor of Medicine, Neurology and Neurosurgery at the University of Texas Health Sciences Center at San Antonio and Principal Investigator of the ReSPECT-LM Clinical Trial, is scheduled to take place on Sunday, October 9, 2022 at 7:00 p.m. 12:00 a.m. Eastern Time to conduct a live, patient-focused webinar entitled A Promising New Targeted Radiation Therapy for Leptomeningeal Metastases in Breast Cancer, Lung Cancer, and Other Malignancies: An Introduction.
Leptomeningeal metastases are cancers of the cerebrospinal fluid and membranes that surround the brain and spinal cord and occur as a result of advanced cancer spread. It is most common in breast cancer, but also occurs in lung cancer and other types of cancer.
The event, part of the Musella Foundation’s webinar series, will be streamed live on the Foundation’s website at virtualtrials.com/webinar/ via a zoom room. Attendees will be asked to enter the digital room 5 minutes prior to the event and will be able to ask questions live or email questions in advance [email protected].
About Andrew Brenner, MD Ph.D.
dr Brenner is the Kolitz/Zachry Endowed Chair in Neuro-Oncology Research and co-directs the Experimental and Developmental Therapies program at UT Health Science Center San Antonio (UTHSCSA) and is a practicing oncologist at Texas Oncology in Austin. His first-in-human trials experience includes involvement in the development of approximately 30 compounds as either a co-investigator or principal investigator since 2008. This includes first-in-class experience (gene therapy, liposomal encapsulated mimetic RNA, liposomal encapsulated therapeutics, metabolic inhibitors, etc.). In this role, he was responsible for protocol preparation, IND and SPA discussions with the FDA, oversight of multicenter trials (including FDA-funded trials), solicitation of bids from CROs, data analysis (primarily PD and some PK) and the presentation of results. He is familiar with all phases of the study implementation.
dr Brenner is a graduate of Texas A&M University, where he received his bachelor’s degree in biochemistry, and his PhD in life sciences and tumor biology from the University of Texas MD Anderson Cancer Center Science Park. dr Brenner received his medical degree from Texas Tech University’s Health Sciences Center and completed his residency in internal medicine at Scott and White Hospital in Lubbock. He completed his fellowship in hematology and medical oncology at the UT Health Science Center.
About the Musella Foundation for Brain Tumor Research & Information
The Musella Foundation is a non-profit 501(c)(3) public charity dedicated to supporting brain cancer patients through emotional and financial support, education, advocacy, and raising funds for brain cancer research. Based in Hewlett, NY, the foundation was founded by Dr. Al Musella, DPM, a podiatrist in private practice in Hewlett. The foundation has awarded over $4.7 million in direct patient assistance to assist patients with treatment. Visit www.virtualtrials.com for more information.
About Plus Therapeutics
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing, manufacturing and commercializing complex and innovative treatments for patients battling cancer and other life-threatening diseases. Our proprietary nanotechnology platform is currently focused on enhanced delivery of a variety of drugs using novel liposomal encapsulation technology. Liposomal encapsulation has been extensively researched since its initial development and has undergone significant technical and commercial advances. Our platform is designed to facilitate new delivery approaches and/or formulations of safe and effective injectable drugs, potentially improving safety, efficacy and convenience for patients and healthcare providers. Visit PlusTherapeutics.com and ReSPECT-Trials.com for more information.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of the United States securities laws. All statements in this press release, other than statements of historical fact, are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “designed,” “will,” “may,” “potential,” “focus,” “prepare,” “next steps,” “possibly” and similar expressions or their negations. Such statements are based on certain assumptions and estimates made by management in light of its experience and perception of historical trends, current conditions, expected future developments and other factors it deems appropriate. These statements include, without limitation, statements regarding: the potential promise of 186RNL, including the potential ability of 186RNL to safely and effectively deliver high doses of radiation directly to the tumor; expectations regarding the future performance of the company, including next steps in the development of the company’s current assets; the Company’s clinical studies, including statements regarding the timing and characteristics of the ReSPECT-LM study; possible adverse effects of 186RNL; the continued evaluation of 186RNL for LM, including through evaluations across a second patient cohort; capital requirements, timing and speed of development; liquidity needs and expected forecast; and the intended capabilities of the Company’s platform and the expected benefits from those capabilities.
The forward-looking statements contained in this press release are subject to a number of risks and uncertainties that could cause actual results to differ materially from those projected in such forward-looking statements. These risks and uncertainties include, but are not limited to: requirements to comply with the terms of the CPRIT grant; the early stage of the Company’s product candidates and therapies and the results of the Company’s research and development activities, including uncertainties related to the clinical trials of its product candidates and therapies; the Company’s liquidity and capitalization and its ability to raise additional cash; the outcome of the company’s partnership/licensing efforts; risks related to laws or regulatory requirements applicable to the Company, market conditions, product performance, litigation or potential litigation and competition, including in the field of regenerative medicine; changes in the CPRIT program; changing sources and uses of cash; and additional risks described under the heading “Risk Factors” in the Company’s filings with the Securities and Exchange Commission, including the Company’s annual and quarterly reports. There may also be future events that are beyond the Company’s ability to predict or control, and its business, financial condition, results of operations and prospects could change in the future. The Company assumes no obligation to update or revise any forward-looking statements to reflect events, trends or circumstances after the date on which they are made, except as required to do so under US federal securities laws.
investor contactPeter Vozzo ICR Westwicke(443) 377-4767[email protected]
media contactTerri Clevenger ICR Westwicke(203) 856-4326[email protected]
Source: Plus Therapeutics Inc.